The role of miR-29b in cancer: regulation, function, and signaling

Yan, Bin; Guo, Qian; Fu, Fajun; Wang, Zhao; Yin, Zhu; Wei, Yongbao; Yang, Jinqiang

doi:10.2147/ott.s75899

Cited by 139 publications

(151 citation statements)

References 71 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…miR-29b discriminates between mode of apoptosis Interestingly, miR-29b is a known tumor-suppressing miRNA that induces apoptosis in different cell systems (32). This is in contrast to our findings that miR-29b protects NSCLC cells from extrinsic apoptosis.…”

Section: S6econtrasting

confidence: 99%

“…miR-29b sensitizes cancer cells to apoptosis by targeting antiapoptotic genes, including MCL1, BCL2, AKT2, CCND2, and CDC42 (reviewed in ref. 32). It also negatively regulates proliferation and migration by targeting genes involved in the regulation of the extracellular matrix and restores erroneous promoter methylation by targeting DNMT3A and 3B.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

miR-29b Mediates NF-κB Signaling in KRAS-Induced Non–Small Cell Lung Cancers

et al. 2016

View full text Add to dashboard Cite

A global understanding of miRNA function in EGFR signaling pathways may provide insights into improving the management of KRAS-mutant lung cancers, which remain relatively recalcitrant to treatment. To identify miRNAs implicated in EGFR signaling, we transduced bronchial epithelial BEAS-2B cells with retroviral vectors expressing KRAS G12V and monitored miRNA expression patterns by microarray analysis. Through this approach, we defined miR-29b as an important target for upregulation by mutant KRAS in non-small cell lung cancers. Cell biologic analyses showed that pharmacologic inhibition of EGFR or MEK was sufficient to reduce levels of miR-29b, while PI3K inhibition had no effect. In KRAS G12V

show abstract

Section: S6econtrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

miR-29b Mediates NF-κB Signaling in KRAS-Induced Non–Small Cell Lung Cancers

et al. 2016

View full text Add to dashboard Cite

show abstract

“…miRNA-29 family miRNAs downregulate cyclindependent kinase 6. It provides a differentiation promoting activity of Runx proteins to be selectively activated in terminally differentiating cells [38,61].…”

Section: Mirna-29mentioning

confidence: 99%

Small Non-Coding RNAs in Regulation of Course and Therapeutic Efficacy in Acute Myeloid Leukemia

Klimenko¹

2018

Myeloid Leukemia

View full text Add to dashboard Cite

Small non-coding RNAs (sncRNAs) are small regulatory molecules, which play key roles in fine-tune of all cell functions. In late 1970s and early 1980s, it was first determined that non-coding RNAs contribute to the cellular regulatory processes. The kingdom of sncRNAs is very numerous and it is clear that functions of different members of this family is different from each other and may be involved in normal and pathologic processes in cell. Recently it was investigated that sncRNAs and long non-coding RNAs play roles in cellular differentiation, proliferation, metabolic processes, bioenergetic regulation, cell death and inter-cellular communications, etc. In embryos, non-coding RNAs control maternal-zygotic transition, the maintenance of pluripotency, the pattering of the body axes, the specification and differentiation of cell types and morphogenesis of organs. Development of hematologic malignancies in humans, their course and regulation of resistance and sensitivity of tumorous cells to therapy are under the control of sncRNAs.

show abstract

“…12 Previous studies have demonstrated that miRNA-29b plays an important role in cancer by regulating cell proliferation, differentiation, and apoptosis. 5,6,13,14 It is usually silenced or downregulated in lung cancer and other types of cancer.…”

Section: Introductionmentioning

confidence: 99%

Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins

Perepelyuk¹,

Maher²,

Lakshmikuttyamma³

et al. 2016

IJN

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are potentially attractive candidates for cancer therapy. However, their therapeutic application is limited by lack of availability of an efficient delivery system to stably deliver these potent molecules intracellularly to cancer cells while avoiding healthy cells. We developed a novel aptamer-hybrid nanoparticle bioconjugate delivery system to selectively deliver miRNA-29b to MUC1-expressing cancer cells. Significant downregulation of oncoproteins DNMT3b and MCL1 was demonstrated by these MUC1 aptamer-functionalized hybrid nanoparticles in A549 cells. Furthermore, downregulation of these oncoproteins led to antiproliferative effect and induction of apoptosis in a superior version when compared with Lipofectamine 2000. This novel aptamer-hybrid nanoparticle bioconjugate delivery system could potentially serve as a platform for intracellular delivery of miRNAs to cancer cells, hence improving the therapeutic outcome of lung cancer.

show abstract

The role of miR-29b in cancer: regulation, function, and signaling

Cited by 139 publications

References 71 publications

miR-29b Mediates NF-κB Signaling in KRAS-Induced Non–Small Cell Lung Cancers

miR-29b Mediates NF-κB Signaling in KRAS-Induced Non–Small Cell Lung Cancers

Small Non-Coding RNAs in Regulation of Course and Therapeutic Efficacy in Acute Myeloid Leukemia

Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins

Contact Info

Product

Resources

About